<DOC>
	<DOCNO>NCT01202591</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness AZD4547 combination fulvestrant vs. fulvestrant alone ER+ breast cancer patient FGFR1 polysomy ( FISH4/5 ) gene amplification ( FISH 6 )</brief_summary>
	<brief_title>Safety Efficacy AZD4547 Combination With Fulvestrant vs. Fulvestrant Alone ER+ Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman ( either bilateral oophorectomy amenorrhoeic 24 month ) Histological confirmation Breast Cancer document ER+ receptor status Safety runin : Relapsing during/within 12 month completion single regimen adjuvant endocrine therapy nonsteroidal AI and/ tamoxifen progression follow 1st line endocrine therapy nonsteroidal AL Rand phase IIa : Received least 1 prior endocrine therapy metastatic setting relapse during/ within 6 month completion adjuvant endocrine therapy ( either nonsteroidal AI tamoxifen combination ) . Chemotherapy administer adjuvant setting permit . Rand phase IIa : Mandatory provision tumour sample confirm FGFR1 polysomy gene amplification . At least one measurable lesion accurately assess CT/MRI/xray baseline follow visit Prior exposure exemestane ( safety runin ) / fulvestrant ( randomized phase IIa ) , agent know inhibit FGFRs . More 1 prior regimen chemotherapy breast cancer ECG recording demonstrate significant abnormality cardiac rate , rhythm conduction History hypersensitivity active inactive excipients AZD4547 exemestane ( safety runin ) fulvestrant ( Randomized phase ) , include castor oil , drug similar chemical structure class AZD4547 exemestane fulvestrant . Randomized phase IIa : bleeding/blood clotting condition would prevent administration fulvestrant injection buttock</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>ER+</keyword>
	<keyword>FGFR1</keyword>
	<keyword>Exemestane</keyword>
	<keyword>AZD4547</keyword>
	<keyword>Fulvestrant</keyword>
</DOC>